Leverna Therapeutics
October 18, 2023
Franciscan B
CNS/Neurological
Company Description: LEVERaging RNA regulatory mechanisms to drug the undruggable with RNA-targeted therapeutics. We identify novel target RNA biology and design targeted therapeutics to increase, inhibit or restore expression/protein function. We currently have 4 programs in CNS and related disease areas, with the lead program (L5001) going into IND in 2025.
State
Massachusetts
Country
United States
Website
https://www.levernatx.com/
CEO/Top Company Official
Lijun Wu
Lead Product in Development
L5001
Development Phase of Primary Product
Discovery
Number Of Unlicensed Products
4
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)